Adalimumab

(Humira®)

Humira®

Drug updated on 11/16/2023

Dosage FormInjection, Single-dose prefilled pen (subcutaneous; 80 mg/0.8 mL, 40 mg/0.8 mL, 40 mg/0.4 mL), Injection, Single-dose prefilled glass syringe (subcutaneous; 80 mg/0.8 mL, 40 mg/0.8 mL, 40 mg/0.4 mL, 20 mg/0.4 mL, 20 mg/0.2 mL, 10 mg/0.2 mL, 10 mg/0.1 mL), Injection , Single-dose glass vial for institutional use only (subcutaneous; 40 mg/0.8 mL)
Drug ClassTumor necrosis factor (TNF) blocker
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For rheumatoid arthritis (RA): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA.
  • For juvenile idiopathic arthritis (JIA): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older.
  • For psoriatic arthritis (PsA): reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA.
  • For ankylosing spondylitis (AS): reducing signs and symptoms in adult patients with active AS.
  • For Crohn’s disease (CD): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
  • For ulcerative colitis (UC): treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older. Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers.
  • For plaque psoriasis (Ps): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
  • For hidradenitis suppurativa (HS): treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.
  • For uveitis (UV): treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.

Product Monograph / Prescribing Information

Document TitleYearSource
Humira (adalimumab) Prescribing Information.2021AbbVie Inc. North Chicago, IL

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Comparison of infliximab with adalimumab for the treatment of non-infectious uveitis: a systematic review and meta-analysis.2023BMC Ophthalmology
Comparison of adalimumab to other targeted therapies in rheumatoid arthritis: results from systematic literature review and meta-analysis.2022Journal of Personalized Medicine
Adalimumab for induction of remission in patients with Crohn's disease: a systematic review and meta-analysis.2022European Journal of Medical Research
Adalimumab effect on pain in hidradenitis suppurativa patients: systematic review and meta-analysis.2022Dermatology Practical & Conceptual
Efficacy and safety of adalimumab in hidradenitis suppurativa: a systematic review and meta-analysis of randomized controlled trials2021Medicine
Efficacy and safety of adalimumab in noninfectious uveitis: a systematic review and meta-analysis of randomized controlled trials.2021Frontiers in Pharmacology
Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis.2021Expert Review of Clinical Immunology
Targeted immune modulators for ulcerative colitis: effectiveness and value2020ICER
Janus kinase inhibitors and biosimilars for rheumatoid arthritis: effectiveness and value.2020ICER
Extension of indication variation assessment report: Humira.2020EMA
An update on clinical safety of adalimumab in treating psoriasis: a systematic review and meta-analysis based on 20 randomized controlled trials.2019Journal of Cosmetic Dermatology
Comparative efficacy and safety of biosimilar adalimumab and originator adalimumab in combination with methotrexate in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.2018Clinical Rheumatology
Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review.2018Drug Design, Development and Therapy

Clinical Practice Guidelines